Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United …
$2.15-11.52%
报价 2026-11-06
市值
$163.8M
EV
$204.2M
PE (TTM)
–
预期 PE (FY2026)
–
52 周区间距高点 -34.8%
$1.18$3.30
筛选结果
pipeline · 2026-11-06Filter✗ 高增长✗ Cheap✗ GARP
market cap below $300M floor
研究结论
还没有研究记录。先生成 L2 基本面报告（约 1–3 分钟），结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
FMP 同行列表 · 2026-05-16| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| STIMNeuronetics, Inc. | $163.8M | -11.5% | +8.8% | 50.7% | – | – | – | |
| OABIOmniAb, Inc. | $733.7M | +4.1% | +58.0% | 63.6% | – | – | 312.2x | |
| PREPrenetics Global Limited | $270M | -1.1% | – | 62.6% | – | – | – | |
| PROFProfound Medical Corp. | $263.4M | +4.8% | – | 71.7% | – | – | – | |
| OSUROraSure Technologies, Inc. | $237.3M | +2.1% | +4.4% | 41% | – | – | – | |
| CDXSCodexis, Inc. | $118.3M | +5.9% | +10.1% | 79.5% | – | – | – | |
| CATXPerspective Therapeutics, Inc. | $95.9M | +6.5% | -54.5% | -419.4% | – | – | – | |
| NYXHNyxoah S.A. | $86.1M | +4.3% | – | 51.3% | – | – | – | |
| 同行中位数 | – | – | +7.2% | 62.6% | – | – | 312.2x |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
暂无季度数据（首次研究运行后填充）。